全文获取类型
收费全文 | 185293篇 |
免费 | 34463篇 |
国内免费 | 3963篇 |
专业分类
耳鼻咽喉 | 5487篇 |
儿科学 | 5987篇 |
妇产科学 | 2908篇 |
基础医学 | 6327篇 |
口腔科学 | 2163篇 |
临床医学 | 30906篇 |
内科学 | 51894篇 |
皮肤病学 | 7962篇 |
神经病学 | 16658篇 |
特种医学 | 7324篇 |
外国民族医学 | 2篇 |
外科学 | 43946篇 |
综合类 | 5951篇 |
现状与发展 | 87篇 |
一般理论 | 25篇 |
预防医学 | 10554篇 |
眼科学 | 4291篇 |
药学 | 4942篇 |
54篇 | |
中国医学 | 2452篇 |
肿瘤学 | 13799篇 |
出版年
2024年 | 851篇 |
2023年 | 5266篇 |
2022年 | 2583篇 |
2021年 | 4850篇 |
2020年 | 7453篇 |
2019年 | 3278篇 |
2018年 | 8626篇 |
2017年 | 8593篇 |
2016年 | 9518篇 |
2015年 | 9934篇 |
2014年 | 17289篇 |
2013年 | 17578篇 |
2012年 | 8436篇 |
2011年 | 8513篇 |
2010年 | 12547篇 |
2009年 | 16081篇 |
2008年 | 8090篇 |
2007年 | 6129篇 |
2006年 | 8351篇 |
2005年 | 5465篇 |
2004年 | 4256篇 |
2003年 | 3140篇 |
2002年 | 3000篇 |
2001年 | 4158篇 |
2000年 | 3319篇 |
1999年 | 3411篇 |
1998年 | 3870篇 |
1997年 | 3626篇 |
1996年 | 3477篇 |
1995年 | 3309篇 |
1994年 | 2055篇 |
1993年 | 1640篇 |
1992年 | 1462篇 |
1991年 | 1495篇 |
1990年 | 1125篇 |
1989年 | 1227篇 |
1988年 | 1060篇 |
1987年 | 894篇 |
1986年 | 940篇 |
1985年 | 761篇 |
1984年 | 602篇 |
1983年 | 575篇 |
1982年 | 580篇 |
1981年 | 442篇 |
1980年 | 395篇 |
1979年 | 328篇 |
1978年 | 360篇 |
1977年 | 427篇 |
1975年 | 290篇 |
1972年 | 314篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
21.
22.
23.
24.
Fraudulent business practices, such as those leading to the Enron scandal and the
conviction of Bernard Madoff, evoke a strong sense of public outrage. But fraudulent or
dishonest actions are not exclusive to the realm of big corporations or to evil
individuals without consciences. Dishonest actions are all too prevalent in everyone’s
daily lives, because people are constantly encountering situations in which they can gain
advantages by cutting corners. Whether it’s adding a few dollars in value to the stolen
items reported on an insurance claim form or dropping outlier data points from a figure to
make a paper sound more interesting, dishonesty is part of the human condition. Here, we
explore how people rationalize dishonesty, the implications for scientific research, and
what can be done to foster a culture of research integrity. 相似文献
25.
骨碎补是历代临床常用中药,具有疗伤止痛、补肾强骨、消风祛斑等功效。其主要含黄酮、苯丙素、三萜、酚酸及其苷等类化学成分,现代研究表明骨碎补具有抗骨质疏松、促进骨折愈合、促软骨再生、护牙健齿、保护肾功能、抗炎、防治中毒性耳聋、降血脂等多种生物活性,开发前景广阔。本文对近年来骨碎补的化学成分、药理作用及临床应用研究进行综述,以期为骨碎补的进一步深入系统的研究和开发利用提供依据。 相似文献
26.
Breast Elastography: How to Perform and Integrate Into a “Best-Practice” Patient Treatment Algorithm
Breast elastography has been available for more than 15 years but is not widely incorporated into clinical practice. Many publications report extremely high accuracy for various breast elastographic techniques. However, results in the literature are extremely variable. This variability is most likely due to variations in technique, a relatively steep learning curve, and variability in methods between vendors. This article describes our protocol for performing breast elastography using both strain elastography and shear wave elastography, which produces high sensitivity and specificity. Additionally, we will describe the most commonly known false-positive and false-negative lesions as well as how to detect them. 相似文献
27.
28.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
29.
30.